| Jennifer J Eddy, MD | |
|
617 W Clairemont Ave, Eau Claire, WI 54701-6223 | |
| (715) 839-5175 | |
| (715) 839-5176 |
| Full Name | Jennifer J Eddy |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 617 W Clairemont Ave, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134151319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 44810 (Wisconsin) | Primary |
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
Mild cognitive impairment (MCI) is often considered an early symptom of Alzheimer's disease (AD). An analysis of genetic risk factors predisposing to MCI is critical for accessing individual predisposition and reliably evaluating the effectiveness of early treatment. In a groundbreaking study published in the February 2010 issue of the Journal of Alzheimer's Disease investigators successfully used artificial neural networks (ANNs) to help understand the causal relation between multiple factors and the occurrence of neurodegenerative disorders.
A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid, Marcela del Río, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre and Fundación Jiménez Díaz has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum.
Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)
CIGNA Corporation today reported shareholders' net income of $330 million, or $1.19 per share, for the fourth quarter of 2009 compared with a shareholders' net loss of $209 million, or $0.77 per share, for the same period last year.
› Verified 8 days ago
| Entity Name | Sacred Heart Hospital Of The Hospital Sisters-3rd Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619355351 PECOS PAC ID: 8729072418 Enrollment ID: O20150814013380 |
News Archive
Mild cognitive impairment (MCI) is often considered an early symptom of Alzheimer's disease (AD). An analysis of genetic risk factors predisposing to MCI is critical for accessing individual predisposition and reliably evaluating the effectiveness of early treatment. In a groundbreaking study published in the February 2010 issue of the Journal of Alzheimer's Disease investigators successfully used artificial neural networks (ANNs) to help understand the causal relation between multiple factors and the occurrence of neurodegenerative disorders.
A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid, Marcela del Río, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre and Fundación Jiménez Díaz has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum.
Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)
CIGNA Corporation today reported shareholders' net income of $330 million, or $1.19 per share, for the fourth quarter of 2009 compared with a shareholders' net loss of $209 million, or $0.77 per share, for the same period last year.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer J Eddy, MD 617 W Clairemont Ave, Eau Claire, WI 54701-6223 Ph: (715) 839-5175 | Jennifer J Eddy, MD 617 W Clairemont Ave, Eau Claire, WI 54701-6223 Ph: (715) 839-5175 |
News Archive
Mild cognitive impairment (MCI) is often considered an early symptom of Alzheimer's disease (AD). An analysis of genetic risk factors predisposing to MCI is critical for accessing individual predisposition and reliably evaluating the effectiveness of early treatment. In a groundbreaking study published in the February 2010 issue of the Journal of Alzheimer's Disease investigators successfully used artificial neural networks (ANNs) to help understand the causal relation between multiple factors and the occurrence of neurodegenerative disorders.
A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid, Marcela del Río, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre and Fundación Jiménez Díaz has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum.
Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile)
CIGNA Corporation today reported shareholders' net income of $330 million, or $1.19 per share, for the fourth quarter of 2009 compared with a shareholders' net loss of $209 million, or $0.77 per share, for the same period last year.
› Verified 8 days ago
Sarah Hotovy, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Dr. Daniel Paul Bobo, MBBS Family Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Dr. Dennis Anthony Auth, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2741 N Clairemont Ave, Eau Claire, WI 54703 Phone: 715-834-0711 | |
Namrata Mehta, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 733 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-838-5222 | |
Dr. Binu Maria Philip Durkee, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2741 N. Clairemont Ave, Eau Claire, WI 54703 Phone: 715-834-0711 Fax: 715-858-3433 | |
Seidu Joamanche Mahama, Family Medicine Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 219-798-1371 | |
Dr. William E Cayley Jr., MD MDIV Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 617 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-839-5175 |